蛋白质精氨酸甲基转移酶与恶性肿瘤发生发展的关系  

Correlation of protein arginine methyltransferase with the occurrence and development of malignancy

作　　者：胡睿[1] 韩丽[1] 肖海波[1] HU Rui;HAN Li;XIAO Hai-bo(Department of Cardiothoracic Surgery,Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine,Shanghai 200092,China)

机构地区：[1]上海交通大学医学院附属新华医院心胸外科,上海200092

出　　处：《世界临床药物》2018年第8期559-562,573,共5页World Clinical Drug

摘　　要：哺乳动物基因组中存在编码9种蛋白质精氨酸甲基转移酶(PRMT)的基因,其蛋白质产物催化3种精氨酸甲基化。蛋白质精氨酸甲基化为多元化修饰,涉及信号转导、基因转录、DNA修复和m RNA剪接等。这些生物学改变与恶性肿瘤的发生与转移相关性研究提示,PRMT的过度表达往往与各种恶性肿瘤有关,因此PRMT可能成为某些恶性肿瘤靶向治疗的可行性目标。本文综述PRMT的分型与生物学功能,PRMT与恶性肿瘤发生发展的关系以及PRMT抑制剂的研究进展。The mammalian genomes contain nine genes of encoding protein arginine methyltransferase（PRMT）, which can produce the protein catalyzing three types of arginine methylation modification. Protein arginine methylation serves as a diversified post-translational protein modification, as well as involves in signal transduction, gene transcription, DNA damage repair and m RNA splicing pathway. Recent studies have associated such biological changes to the malignancy development and metastasis. Overexpression of PRMT is often associated with various malignancies, which highlights them as potential ideal therapeutic targets for malignancy treatment. This review summarizes the classification and biological functions of PRMT, and its correlation with the occurrence and development of various malignancies including the research progress of PRMT inhibitors.

关 键 词：蛋白质精氨酸甲基转移酶(PRMT) 甲基化 恶性肿瘤 靶向治疗 

分 类 号：R730[医药卫生—肿瘤] R979.19[医药卫生—临床医学]